{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 25,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/18",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.18,
        "x": 0.44,
        "y": 0.35
      },
      "kind": "chart",
      "text": "NXP900 - IC50 for YAP1 nuclear localization: 24.3nM",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "171317a9-9b30-40ff-9531-be47b28c7d59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Hippo pathway signaling diagram showing YES1/SRC interaction with YAP/TAZ",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6f54cab-91c4-43a8-98b1-e1676e1e0abe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.44,
        "y": 0.18
      },
      "kind": "image",
      "text": "Microscopy images of Low vs High Nuclear YAP",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "778234ef-70f3-4858-8159-913d3f5d9102",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.66,
        "y": 0.2
      },
      "kind": "list",
      "text": "Genetic alterations in the hippo pathway (FAT1-4, YAP1, TAZ) are highly prevalent in cancers of squamous cell origin and confer sensitivity to NXP900 -> patient selection. YES1 drives tumor growth via activating phosphorylation and nuclear localization of YAP1 -> Target is central to disease etiology. Significant unmet medical need opportunities within the squamous cancer universe -> Regulatory opportunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f913433-2a6e-41c7-adb0-8e9d03b421b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Targeting YES1 in Cancers of Squamous Cell Origin",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2746de47-fc4e-4c1b-aa4a-0fb9787997b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "Single agent development strategy",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02b73ccb-7d5c-4111-a1ce-a7b07d7d6f02",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
      "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
      "position": 1,
      "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}